With with GLP-1 drugs, gastrointestinal issues, such as nausea, vomiting, constipation, and gastroesophageal reflux disease, ...

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...

Novo Nordisk’s NVO amycretin, which targets GLP-1 and amylin in one molecule, generated 24% placebo-adjusted weight loss in a ...

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

Oprah Winfrey recently detailed how taking weight loss drugs shifted her longtime mindset about what she described as “thin ...

A novel GLP-1 and amylin receptor agonist featured a safety profile similar to other incretin-based therapies and conferred a ...

The readout comes on the heels of CagriSema’s disappointing Phase III performance, where it missed Novo’s projection of 25% ...

Oprah Winfrey revealed that earlier, she used to believe that “they ate better foods” and were able to stick to their diets ...

Oprah Winfrey has admitted to using an unnamed weight-loss drug to manage her weight and says doing so has changed her ...

Oprah Winfrey is spilling the truth about “thin people” after her diet drug journey. Knewz.com can reveal the media mogul, ...

For people with diabetes, the use of GLP-1 RAs is associated with reduced risk for certain disorders and conditions.